High DHEAS/free testosterone ratio is related to better metabolic parameters in women with PCOS

References

• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–36
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus working group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
   PubMedGoogle Scholar
• Cussons AJ, Watts GF, Burke V, et al. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008;23:2352–8
   PubMed Web of Science ®Google Scholar
• Korhonen S, Hippelainen M, Vanhala M, et al. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 2003;79:1327–34
   PubMed Web of Science ®Google Scholar
• Carmina E, Gonzalez F, Chang L, Lobo RA. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. Obstet Gynecol 1995;85:971–6
   PubMed Web of Science ®Google Scholar
• Loughlin T, Cunningham S, Moore A, et al. Adrenal abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab 1986;62:142–7
   PubMed Web of Science ®Google Scholar
• Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2005;62:644–9
   PubMed Web of Science ®Google Scholar
• Aprinodze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;90:1929–35
   PubMedGoogle Scholar
• Köşüş N, Köşüş A, Kamalak Z, et al. Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome. Gynecol Endocrinol 2012;28:611–14
   PubMed Web of Science ®Google Scholar
• Lerchbaum E, Schwetz V, Giuliani A, et al. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil Steril 2012;98:1318–25
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Metab Endocrinol 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Brennan K, Huang A, Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 2009;91:1848–52
   PubMed Web of Science ®Google Scholar
• Buffington CK, Givens JR, Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females. Diabetes 1991;40:693–700
   PubMed Web of Science ®Google Scholar
• McKenna TJ, Cunningham SK. The pathogenesis of adrenal and extra adrenal hyperandrogenism. J Steroid Biochem Mol Biol 1993;45:117–21
   PubMedGoogle Scholar
• Wu XK, Zhou SY, Sallinen K, et al. Ovarian-adrenal cross-talk in polycystic ovary syndrome: evidence from wedge resection. Eur J Endocrinol 2000;143:383–8
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, De Lorenzo D, Ricci C, Teti G. Ovarian influence on adrenal androgen secretion in polycystic ovary syndrome. Fertil Steril 1995;63:734–41
   PubMed Web of Science ®Google Scholar
• Matteri RK, Stanczyk FZ, Cassidenti DL, et al. The ovarian contribution to peripherally derived serum C19 conjugates. J Clin Endocrinol Metab 1992;75:768–72
   PubMedGoogle Scholar
• Gonzalez F, Hatala DA, Speroff L. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome. Am J Obstet Gynecol 1991;165:535–45
   PubMedGoogle Scholar
• Savastano S, Belfiore A, Guida B, et al. Role of dehydroepiandrosterone sulfate levels on body composition after laparoscopic adjustable gastric banding in pre-menopausal morbidly obese women. J Endocrinol Invest 2005;28:509–15
   PubMed Web of Science ®Google Scholar
• Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 1993;17:643–9
   PubMed Web of Science ®Google Scholar
• Dong Z, Chen X, Li L, et al. Free testosterone level correlated with the metabolic abnormalities dependent on central obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2012;120:355–60
   PubMed Web of Science ®Google Scholar
• Chen MJ, Chen CD, Yang JH, et al. High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome. Hum Reprod 2011;26:227–34
   PubMed Web of Science ®Google Scholar
• Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999;84:1527–33
   PubMed Web of Science ®Google Scholar
• Jedrzejuk D, Medras M, Millewicz A, Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male 2003;6:151–6
   PubMedGoogle Scholar
• Villereal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men. JAMA 2004;292:2243–8
   PubMedGoogle Scholar
• Azziz R, Ehrmann DA, Legro RS, et al. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003;79:932–7
   PubMed Web of Science ®Google Scholar
• Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003;17:51–6
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767–74
   PubMed Web of Science ®Google Scholar
• Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001;16:1625–31
   PubMed Web of Science ®Google Scholar
• Güdücü N, Görmüş U, Kutay SS, et al. Endogenous sex hormones and their association with cardiovascular risk factors in postmenopausal women. J Endocrinol Invest 2013;36:582–92
   Google Scholar
• Gambineri A, Repaci A, Patton L, et al. Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 2009;19:797–804
   PubMed Web of Science ®Google Scholar
• Haring R, Xanthakis V, Coviello A, et al. Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study. Int J Androl 2012;35:775–82
   PubMed Web of Science ®Google Scholar